Literature DB >> 6389331

Non-Hodgkin's lymphoma.

S C Gulati, C Gulati, R Vega, L Gandola, J Yopp, R Dinsmore, R O'Reilly, B Clarkson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6389331     DOI： 10.1007/bf02957737

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN： 0019-5456            Impact factor:   1.967


× No keyword cloud information.
  21 in total

Review 1.  Retroviruses as etiologic agents of some animal and human leukemias and lymphomas and as tools for elucidating the molecular mechanism of leukemogenesis.

Authors:  R C Gallo; F Wong-Staal
Journal:  Blood       Date:  1982-09       Impact factor: 22.113

2.  Treatment of advanced diffuse histiocytic lymphoma: an analysis of prognostic variables.

Authors:  B Koziner; C Little; S Passe; H T Thaler; R Sklaroff; D J Straus; B J Lee; B D Clarkson
Journal:  Cancer       Date:  1982-04-15       Impact factor: 6.860

3.  Identification of the constant chromosome regions involved in human hematologic malignant disease.

Authors:  J D Rowley
Journal:  Science       Date:  1982-05-14       Impact factor: 47.728

4.  A randomized trial of combined modality therapy of childhood non-Hodgkin's lymphoma.

Authors:  S B Murphy; H O Hustu
Journal:  Cancer       Date:  1980-02-15       Impact factor: 6.860

5.  Fatal graft-versus-host disease following blood transfusion in Hodgkin's disease documented by HLA typing.

Authors:  R E Dinsmore; D J Straus; M S Pollack; J M Woodruff; T J Garrett; C W Young; B D Clarkson; B Dupont
Journal:  Blood       Date:  1980-05       Impact factor: 22.113

6.  Non-Hodgkin's lymphoma in children. A comparative study of two modalities of therapy.

Authors:  N Wollner; J H Burchenal; P H Lieberman; P Exelby; G D'Angio; M L Murphy
Journal:  Cancer       Date:  1976-01       Impact factor: 6.860

7.  LSA2-L2 protocol treatment of stage IV non-Hodgkin's lymphoma in children with partial and extensive bone marrow involvement.

Authors:  L Duque-Hammershaimb; N Wollner; D R Miller
Journal:  Cancer       Date:  1983-07-01       Impact factor: 6.860

8.  Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP).

Authors:  J O Armitage; F R Dick; M P Corder; S C Garneau; C E Platz; D J Slymen
Journal:  Cancer       Date:  1982-11-01       Impact factor: 6.860

9.  Malignant lymphoma of true histiocytic (monocyte/macrophage) origin.

Authors:  P Isaacson; D H Wright; D B Jones
Journal:  Cancer       Date:  1983-01-01       Impact factor: 6.860

10.  Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma.

Authors:  R I Fisher; S M Hubbard; V T DeVita; C W Berard; R Wesley; J Cossman; R C Young
Journal:  Blood       Date:  1981-07       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.